Clinical trials: Hepatic Cancer, open to volunteers
Pancreas Cancer, Lung Cancer
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.
- Conditions
- Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
- Trial name
- NCT06196294
- Testing
- Cell therapy for solid tumors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepato Cellular Carcinoma (HCC), Immunotherapy
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.
- Trial name
- NCT07461675
- Testing
- Atezolizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Geneva, Switzerland
Hepatocellular Carcinoma (HCC)
Improving the Use of Immunotherapy to Treat Liver Cancer
This project targets patients with a form of primary liver cancer, specifically "hepatocellular carcinoma". This disease often develops in the context of a chronically diseased liver, caused by viral infections, excessive alcohol…
- Trial name
- IO-MARC (NCT07623265)
- Testing
- Blood and tissue sample
- Where
- 4 sites in Belgium
- Volunteers
- 300 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hepatocellular Carcinoma
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment.
- Trial name
- NCT07235410
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma (HCC), Glypican-3
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
- Conditions
- Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
- Trial name
- NCT07677774
- Testing
- GPC3-targeted PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Breast Cancer, eHealth
Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects
Chemotherapy induces side effects varying in severity, impacting patients' quality of life and necessitating unplanned hospital care. Patient-reported outcomes (PROs) could aid in early detection and management of side effects.
- Conditions
- Breast Cancer, eHealth, Symptom Monitoring, Self Management
- Trial name
- eChemoCoach (NCT06424054)
- Testing
- eChemoCoach
- Volunteers
- 746 people
- Sponsor
- Noordwest Ziekenhuisgroep
Hepatocellular Carcinoma
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
- Trial name
- NCT06244225
- Testing
- Donafenib； Sintilimab； HAIC
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hepatocellular Carcinoma, Neoadjuvant Therapy
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Surgical resection is the preferred therapeutic modality for patients with resectable hepatocellular carcinoma (HCC). However, the recurrence rate of HCC remains up to 70%.
- Conditions
- Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
- Trial name
- NCT07324824
- Testing
- sintilimab combined with bevacizumab biosimilar
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma, Cirrhosis
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
This phase Ib/II trial tests the safety, side effects, and best dose of zanzalintinib and how well it works in treating patients with hepatocellular (liver) cancer that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07042919
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Devalingam Mahalingam
Hepatocellular Carcinoma (HCC)
Streamlining Radioembolization for Small HCC
In patients who has no sign suggesting high lung shunt fraction (TIPS, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel, tumor size < 5cm), radioembolization is performed without…
- Trial name
- ISTAR-02 (NCT06979219)
- Where
- 5 sites in South Korea
- Volunteers
- 146 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Recurrent Liver Cancer, Primary Liver Cancer
Recurrent Liver Cancer: Reconceptualization and Reevaluation
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer.
- Trial name
- NCT06430983
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Liver Tumours, Liver Cancer (Primary and Metastatic)
Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy
The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy.
- Conditions
- Liver Tumours, Liver Cancer (Primary and Metastatic), Liver Resection, Liver Hypertrophy
- Trial name
- I-GROWtoh (NCT07445412)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lung Cancer (Diagnosis), Liver Cancer, Adult
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with…
- Conditions
- Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers
- Trial name
- SPEED (NCT07824583)
- Testing
- Next Generation Delivery System (NGDS)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Varian, a Siemens Healthineers Company
Colorectal Cancer, Metastatic Liver Cancer
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Multicentric prospective and observational study to assess the 5-year overall survival in a cohort of patients with unresectable liver-only colorectal metastases, well controlled by chemotherapy prior to liver transplantation.
- Conditions
- Colorectal Cancer, Metastatic Liver Cancer, Liver Metastases
- Trial name
- TRASMETIR (NCT04616495)
- Testing
- Liver transplantation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario La Fe
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Hepatocellular Carcinoma, Narrow Margin
Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
Hepatocellular carcinoma (HCC) is the sixth prevalent malignancy worldwide. Although surgical excision is considered the standard treatment for resectable HCC, a high rate of postoperative recurrence was observed after partial…
- Conditions
- Hepatocellular Carcinoma, Narrow Margin, Adjuvant Stereotactic Body Radiotherapy, Hepatectomy
- Trial name
- NCT05602974
- Testing
- stereotactic body radiation therapy, regular follow-up
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Sialic Acid in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for approximately 90% of the cases of liver cancer and is associated with high morbidity and mortality.
- Trial name
- NCT06836518
- Testing
- serum sialic acid
- Volunteers
- 100 people
- Sponsor
- Sohag University
Liver Cancer, Liver Metastasis Colon Cancer
Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms
The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies.
- Conditions
- Liver Cancer, Liver Metastasis Colon Cancer, Kidney Cancer, Renal Cell Carcinoma
- Trial name
- NCT03981497
- Testing
- Microwave ablation (MWA)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Francesco De Cobelli
Hepatecellular Carcinoma
Affordable Made-in-India Microspheres for Liver Cancer Therapy
Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide…
- Trial name
- ReLIVE (NCT07436988)
- Testing
- 90Y-Theraspheres, 188Re-Microspheres
- Where
- 5 sites in India
- Volunteers
- 18 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.